Drugdiscovery >> Drugs >> News
5287
Views
Femara beneficial for breast cancer patients treated with tamoxifen - drugdiscovery.com
Femara beneficial for breast cancer patients treated with tamoxifen - drugdiscovery.com


The results of a large study show that femara significantly reduces the risk of breast cancer reccurence in patients who were treated both drugs.
Read More >>


Tags: breast cancer, femara, tamoxifen, risk, recurrence - August 12, 2013
Related Articles
2386
Views
Tamoxifen may prevent breast cancer Tamoxifen may prevent breast cancer
The results of the largest to date global study suggest that women who carry the BRCA1 or BRCA2 mutation which put them at high risk of developing breast cancer could benefit from taking tamoxifen fo Read More >>

Tags: Tamoxifen, breast cancer, prevention, BRCA 1, BRCA 2, mutation, high risk

3658
Views
Tamoxifen raises the probability of chemotherapy-induced amenorrhea Tamoxifen raises the probability of chemotherapy-induced amenorrhea
The results of a multicenter survey of premenopausal women diagnosed and treated for invasive breast cancer show that tamoxifen therapy and age at treatment are important predictors of chemotherapy-i Read More >>

Tags: tamoxifen, breast cancer, amenorrhea, chemotherapy-induced amenorrhea, age, premenopause

4674
Views
 Afatinib  is beneficial  for patients with distinct subtype of lung cancer Afatinib is beneficial for patients with distinct subtype of lung cancer
The results of LUX-Lung phase III trial show that Afatinib delays tumour growth and improves disease-related symptoms in patients with EGFR mutation positive, advanced non-small cell lung cancer (NSC Read More >>

Tags: Afatinib, lung cancer, EGFR mutation

5220
Views
Perjeta approved for early breast cancer Perjeta approved for early breast cancer
The FDA has granted accelerated approval to Roche's Perjeta (pertuzumab) as part of a complete treatment regimen for patients with HER2-positive, locally advanced, inflammatory or early stage breast c Read More >>

Tags: Perjeta, pertuzumab, Roche, FDA, approval, early breast cancer, inflammatory breast cancer, neoadjuvant, treatment

5137
Views
The growth of breast cancer market in the future The growth of breast cancer market in the future
According to findings from Decision resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, the breast cancer market will grow to more than $15 bil Read More >>

Tags: breast cancer, drugs, market, perjeta, afinitor, herceptin, palbociclib

5444
Views
Eisai’s breast cancer drug launched in Russia Eisai’s breast cancer drug launched in Russia
Halaven (eribulin mesylate), a novel anticancer agent developed by Eisai, has now been launched in Russia, where it is approved for the treatment of locally advanced or metastatic breast cancer previo Read More >>

Tags: Eisai, halaven, eribulin mesylate, breast cancer, Russia

4195
Views
Decitabine could help treat breast cancer Decitabine could help treat breast cancer
Decitabine is currently licensed for the treatment of acute myeloid leukaemia. It is one of the rare, FDA approved cancer drugs, that work as DNA methylation modifiers. The results of an animal study Read More >>

Tags: decitabine, breast cancer, study, leukaemia, acute myeloid leukaemia, epigenetics, methylation, PRKD1

3930
Views
Statins beneficial  for  severe asthma patients  Statins beneficial for severe asthma patients
The addition of statins to their inhaler therapy could significantly improve asthma control in patients suffering from severe asthma, according to a new study. Read More >>

Tags: statins, asthma, benefit, therapy

3017
Views
Combining tofacitinib with DMARDs beneficial for patients with active rheumatoid arthritis Combining tofacitinib with DMARDs beneficial for patients with active rheumatoid arthritis
According to a recent study, tofacitinib, in addition to disease-modifying anti-rheumatic drugs (DMARDs),showed safe and effective in improving symptoms in patients with active rheumatoid arthritis Read More >>

Tags: rheumatoid arthritis, tofacitinib, Janus kinase inhibitor, anti-rheumatic drugs

2091
Views
FDA panel recommends Perjeta for neoadjuvant use in early breast cancer FDA panel recommends Perjeta for neoadjuvant use in early breast cancer
With FDA’s aim to get cutting-edge treatments to early-stage patients in hopes of stopping the disease in its tracks, Roche’s Perjeta is on its way to get a new indication for the treatment of pat Read More >>

Tags: Perjeta, early breast cancer, HER2-positive, neoadjuvant, before surgery

MOST VIEWED
HOME | ABOUT | PRIVACY POLICY | TERMS & CONDITIONS | ADVERTISE | CONTACT
All rights reserved drugdiscovery.com 2013